PI3Kγ inhibition: Towards an 'aspirin of the 21st century'?

Nature Reviews Drug Discovery

Volumn 5, Issue 11, 2006, Pages 903-918

  Rückle, Thomas ^a   Schwarz, Matthias K ^a   Rommel, Christian ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; BENZOXAZINE DERIVATIVE; BENZOXAZINONE DERIVATIVE; IMIDAZO[1,2 C]QUINAZOLINE DERIVATIVE; MYRICETIN; NEUTRALIZING ANTIBODY; NORVIRIDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE P100 GAMMA; PHOSPHOTRANSFERASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; QUERCETIN; STAUROSPORINE; TETRAZOLE DERIVATIVE; TG 100 115; UNCLASSIFIED DRUG; VIRIDIN; WORTMANNIN; CHEMOKINE; CHEMOKINE RECEPTOR; ENZYME INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GENETIC ANALYSIS; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HEMATOPOIESIS; MOUSE; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMOKINES; ENZYME INHIBITORS; HEMATOPOIESIS; HUMANS; MICE; RECEPTORS, CHEMOKINE;

EID: 33750525089     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2145     Document Type: Review

References (160)

1. Finan, P. M. & Ward, S. G. PI3-kinase inhibition: A target for therapeutic intervention. Protein Tyrosine Kinases 53-69 (2006).
2. Wymann, M. P. & Marone, R. Phosphoinositide 3-kinase in disease: Timing, location, and scaffolding. Curr. Opin. Cell Biol. 17, 141-149 (2005).
3. Fishman, M. C. & Porter, J. A. Pharmaceuticals: A new grammar for drug discovery. Nature 437, 491-493 (2005).
4. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002).
5. Rameh, L. E. & Cantley, L. C. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 274, 8347-8350 (1999).
6. Pasquali, C. & Rommel, C. Fishing for pharmaceutically relevant phosphoinositide-binding proteins using chemical proteomics. Functional Lipidomics 211-241 (2006).
7. Weiss-Haljiti, C. et al. Involvement of phosphoinositide 3-kinase γ, Rac, and PAK signaling in chemokine-induced macrophage migration. J. Biol. Chem. 41, 43273-84 (2004).
8. Foster, F. M., Traer, C. M., Abraham, S. M. & Fry, M. J. The phosphoinositide (PI) 3-kinase family. J. Cell Sci. 116, 3037-3040 (2003).
9. Vanhaesebroeck, B. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602 (2001).
10. Engelman J. A., Luo J., Cantley L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606-619 (2006).
11. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. & Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963-10968 (1999).
12. Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mammalian Genome 13, 169-172 (2002).
13. Foukas, L. C., et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370 (2006).
14. Knight, Z. A., et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733-747 (2006).
15. Samuels, Y. et al. Brevia: High frequency of mutations of the PIK3Ca gene in human cancers. Science 304, 554 (2004).
16. Bader, A. G., Kang, S., Zhao, L. Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nature Rev. Cancer 5, 921-929 (2005).
17. Jackson, S. P. PI3-kinase p110β: A new target for antithrombotic therapy. Nature Med. 11, 507-514 (2005).
18. Okkenhaug, K., Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nature Rev. Immunol. 3, 317-330 (2003).
19. Stephens, L. et al. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G-protein βγ subunits. Cell 77, 83-93 (1994).
20. Stoyanov, B. et al. Cloning and characterization of a G-protein activated human phosphoinositide 3-kinase. Science 269, 690-693 (1995).
21. Stephens, L. R. et al. The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89, 105-114 (1997).
22. Krugmann, S., Hawkins, P. T., Pryer, N. & Braselmann, S. Characterizing the interactions between the two subunits of the p101/p110 phosphoinositide 3-kinase and their role in the activation of this enzyme by G subunits. J. Biol. Chem. 274, 17152-17158 (1999).
23. Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ. Cell 103, 931-943 (2000).
24. Suire, S., Hawkins, P. & Stephens, L. Activation of phosphoinositide 3-kinase γ by Ras. Curr. Biol. 12, 1068-1075 (2002).
25. Bondeva, T. et al. Bifurcation of lipid and protein kinase signals of PI3Kγ to the protein kinases PKB and MAPK. Science. 282, 293-296 (1998).
26. Lopez-Ilasaca, M., Gutkind, J. S. & Wetzker, R. Phosphoinositide 3-kinase γ is a mediator of Gβγ-dependent Jun kinase activation. J. Biol. Chem. 273, 2505-2508 (1998).
27. Bernstein, H.-G., Keilhoff, G., Reiser, M., Freese, S. & Wetzker, R. Tissue distribution and subcellular localization of a G-protein coupled phosphoinositide 3-kinase. An immunohistochemical study. Cell. Mol. Biol. 44, 973-983 (1998).
28. Wetzker, R. & Rommel, C. Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr. Pharm. Des. 10, 1915-1922 (2004).
29. McCudden, C. R., Hains, M. D., Kimple, R. J., Siderovski, D. P. & Willard, F. S. G-protein signaling: Back to the future. Cell. Mol. Life Sci. 62, 551-577 (2005).
30. Hepler, J. R. & Gilman, A. G. G proteins. Trends Biochem. Sci. 17, 383-387 (1992).
31. Taussig, R., Tang, W. J., Hepler, J. R. & Gilman, A. G. Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases. J. Biol. Chem. 269, 6093-6100 (1994).
32. Lee, S. B., Shin, S. H., Hepler, J. R., Gilman, A. G. & Rhee, S. G. Activation of phospholipase C-β2 mutants by G protein αθ and βγ subunits. J. Biol. Chem. 268, 25952-25957 (1993).
33. Li, Z. et al. Roles of PLC-β2 and-β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287, 1046-1049 (2000).
34. Chodniewicz, D. & Zhelev, D. V. Chemoattractant receptor-stimulated F-actin polymerization in the human neutrophil is signaled by 2 distinct pathways. Blood 101, 1181-1184 (2003).
35. Chung, C. Y., Lee, S., Briscoe, C., Ellsworth, C. & Firtel, R. A. Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells. Proc. Natl Acad. Sci. USA 97, 5225-5230 (2000).
36. Dascal, N. Ion-channel regulation by G proteins. Trends Endocrinol. Metab. 12, 391-398 (2001).
37. Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 287, 1049-1053 (2000).
38. Sasaki, T. et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040-1046 (2000).
39. Patrucco, E. et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell 118, 375-387 (2004).
40. Barbier, M. et al. Tumour biology. Weakening link to colorectal cancer? Nature 413, 796 (2001).
41. Proudfoot, A. E. I., Power, C. A., Rommel, C. & Wells, T. N. C. Strategies for chemokine antagonists as therapeutics. Semin. Immunol. 15, 57-65 (2003).
42. Johnson, Z. et al. Chemokine inhibition - why, when, where, which and how? Biochem. Soc. Trans. 32, 366-377 (2004).
43. Onuffer, J. J. & Horuk, R. Chemokines, chemokine receptors and small-molecule antagonists: Recent developments. Trends Pharm. Sci. 23, 459-467 (2002).
44. Ribeiro, S. & Horuk, R. The clinical potential of chemokine receptor antagonists. Pharm. Ther. 107, 44-58 (2005).
45. Schroff, R. W. et al. The toxicology of chemokine inhibition. Mini-Rev. Med. Chem. 5, 849-855 (2005).
46. Arcaro, A. & Wymann, M. P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-triphosphate in neutrophil responses. Biochem. J. 296, 297-301 (1993).
47. Vlahos, C. J., Matter, W. F., Hui, K. Y. & Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248 (1994).
48. Al-Aoukaty, A., Rolstad, B. & Maghazachi, A. A. Recruitment of pleckstrin and phosphoinositide 3-kinase γ into the cell membranes, and their association with Gβγ after activation of NK cells with chemokines. J. Immunol. 162, 3249-3255 (1999).
49. Pillinger, M. H. & Abramson, S. B. The neutrophil in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21, 691-714 (1995).
50. Thomas, M. J. et al. Airway inflammation: Chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur. J. Immunol. 35, 1283-1291 (2005).
51. Condliffe, A. M. et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432-1440 (2005).
52. Puri, K. D. et al. The role of endothelial PI3Kγ activity in neutrophil trafficking. Blood 106, 150-157 (2005).
53. Jones, G. E. et al. Requirement for PI 3-kinase γ in macrophage migration to MCP-1 and CSF-1. Exp. Cell Res. 290, 120-131 (2003).
54. Del Prete, A. et al. Defective dendritic cell migration and activation of adaptive immunity in PI3Kγ-deficient mice. EMBO J. 23, 3505-3515 (2004).
55. Pinho, V. et al. Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: Importance for the resolution of allergic inflammation. J. Leukoc. Biol. 77, 800-810 (2005).
56. Reif, K. et al. Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing. J. Immunol. 173, 2236-2240 (2004).
57. Ward, S. G. Do phosphoinositide 3-kinases direct lymphocyte navigation? Trends Immunol. 25, 67-74 (2004).
58. Cronshaw, D. G., Owen, C., Brown, Z. & Ward, S. G. Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis. J. Immunol. 172, 7761-7770 (2004).
59. Barber, D. F. et al. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J. Immunol. 176, 589-593 (2006).
60. Nombela-Arrieta, C. et al. Differential requirements for DOCK2 and phosphoinositide-3-kinase γ during T and B lymphocyte homing. Immunity 21, 429-441 (2004).
61. Gilfillan, A. M. & Tkaczyk, C. Integrated signalling pathways for mast-cell activation. Nature Rev. Immunol. 6, 218-230 (2006).
62. Laffargue, M. et al. Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity 16, 441-451 (2002).
63. Hirsch, E. et al. Resistance to thromboembolism in PI3Kγ-deficient mice. FASEB J. 15, 2019-2021 (2001).
64. Lian, L. et al. The relative role of PLCβ and PI3Kγ in platelet activation. Blood 106, 110-117 (2005).
65. Deane, J. A. & Fruman, D. A. Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu. Rev. Immunol. 22, 563-598 (2004).
66. Rodriguez-Borlado, L. et al. Phosphatidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio. J. Immunol. 170, 4475-4482 (2003).
67. 2+ channels via phosphoinositide 3-kinase. FASEB J. 13, 685-694 (1999).
68. 2+-channel current in vascular smooth muscle cells is inhibited by lavendustin-A and LY-294002. Pfluegers Archiv. 437, 317-323 (1999).
69. Quignard, J-F. et al. Phosphoinositide 3-kinase γ mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J. Biol. Chem. 276, 32545-32551 (2001).
70. Steinberg, S. F. PI3King the L-type calcium channel activation mechanism. Circulation Res. 89, 641-644 (2001).
71. Vecchione, C. et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ. J. Exp. Med. 201, 1217-1228 (2005).
72. Welch, H. C., Coadwell, W. J., Stephens, L. R. & Hawkins, P. T. Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett. 546, 93-97 (2003).
73. Esposito, G., Rapacciuolo, A., Naga Prasad, S. V. & Rockman, H. A. Cardiac hypertrophy: Role of G protein-coupled receptors. J. Card. Fail. 8, S409-S414 (2002).
74. Crackower, M. A. et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110, 737-749 (2002).
75. Oudit, G. Y. et al. Phosphoinositide 3-kinase γ-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108, 2147-2152 (2003).
76. Fife, B. T., Huffnagle, G. B., Kuziel, W. A. & Karpus, W. J. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192, 899-905 (2000).
77. Grant, E. P. et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 196, 1461-1471 (2002).
78. Szekanecz, Z., Kim, J. & Koch, A. E. Chemokines and chemokine receptors in reumatoid arthritis. Semin. Immunol. 15, 15-21 (2003).
79. Lee, D. M. et al. Mast cells: A cellular link between autoantibodies and inflammatory arthritis. Science 297, 1689-1692 (2002).
80. Camps, M. et al. A small molecule inhibitor of PI3Kγ suppresses joint inflammation and damage in a murine model of rheumatoid arthritis. Nature Med. 11, 936-943 (2005).
81. Lupia, E. et al. Ablation of phosphoinositide 3-kinase-γ reduces the severity of acute pancreatitis. Am. J. Pathol. 165, 2003-2011 (2004).
82. Barber, D. F. et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in murine models of systemic lupus. Nature Med. 11, 933-935 (2005).
83. Vanhaesebroeck, B., Rohn, J. L. & Waterfield, M. D. Gene targeting: attention to detail. Cell 118, 274-276 (2004).
84. Clayton, E. et al. A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196, 753-763 (2002).
85. Jou, S-T., Carpino, N., Takahashi, Y., Piekorz, R., Chao, J-R., Carpino, N., Wang, D. & Ihle, J. N. Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22, 8580-8591 (2002).
86. Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297, 1031-1034 (2002).
87. Walker, E. H., Perisic, O., Ried, C., Stephens, L. & Williams, R. L. Structural insights into phosphoinositide 3-kinase signaling. Nature 402, 313-320 (1999).
88. Walker, E. H. et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myrecetin, and staurosporin. Mol. Cell 6, 909-919 (2000).
89. Wipf, P. & Halter, R. J. Chemistry and biology of wortmannin. Org. Biomol. Chem. 3, 2053-2061 (2005).
90. Ward, S., Sotsios, Y., Dowden, J., Bruce, I. & Finan, P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 10, 207-213 (2003).
91. Dodge, J. A., Sato, M. & Vlahos, C. J. Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof. US Patent 05,726,167 (1995).
92. Ihle, N. T. et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3, 763-772 (2004).
93. Wymann, M. P. et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate. Mol. Cell. Biol. 16, 1722-1733 (1996).
94. Sadhu C., Masinosky B., Dick K., Sowell C. G. & Staunton D. E. Essential role of phosphoinositide 3-kinase in neutrophil directional movement. J. Immunol. 170, 2647-2654 (2003).
95. Pomel, V. et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem. 49, 3857-3871 (2006).
96. Knight, Z. A. et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12, 4749-4759 (2004).
97. Dermatakis, A. ATP-competitive inhibitors of cyclindependent kinases. Front. Biotech. Pharm. 3, 125-156 (2002).
98. Misra, R. N. et al. N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 47, 1719-1728 (2004).
99. Helal, C. J. et al. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. Lett. 14, 5521-5525 (2004).
100. Kim, K. S. et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem. 45, 3905-3927 (2002).
101. Wityak, J. et al. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56Lck. Bioorg. Med. Chem. Lett. 13, 4007-4010 (2003).
102. Bruce, I. et al. 5-Phenylthiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors for the treatment of allergic and inflammatory diseases. PCT Int. Appl., WO-03072557 (2003).
103. Bloomfield, G. C., Bruce, I., Leblanc, C., Oza, M. S. & Whitehead, L. Preparation of 5-phenylthiazoles as phosphatidylinositol 3-kinase (PI3 kinase) inhibitors. PCT Int. Appl., WO-04078754 (2004).
104. Bruce, I. et al. Preparation of pyrazinyl/pyridinyl thiazolylamines as inhibitors of phosphatidylinositol 3-kinase. PCT Int. Appl., WO-04096797 (2004).
105. Bloomfield, G. C. et al. Preparation of phenylthiazolylureas as inhibitors of phosphatidylinositol 3-kinase. PCT Int. Appl., WO-05021519 (2005).
106. Quattropani, A. et al. Preparation of thiazole derivatives as modulators of the phosphoinositide 3-kinases (PI3Ks). PCT Int. Appl., WO-05068444 (2005).
107. Breitfelder, S. et al. PI3 kinases. PCT Int. Appl., WO-06040279 (2006).
108. Barvian, N. C., Kolz, C. N., Para, K. S., Patt, W. C. & Visnick, M. Preparation of benzoxazin-3-ones and derivatives as inhibitors of PI3K kinase for treating inflammations, cardiovascular diseases and cancers. PCT Int. Appl., WO-04052373 (2004).
109. Gogliotti, R. D., Muccioli, K. L., Para, K. S. & Visnick, M. Preparation of benzoxazines and related compounds as inhibitors of PI3Ks. PCT Int. Appl., WO-04056820 (2004).
110. Lanni, T. B. Jr et al. Design and synthesis of 3-methyl-5-substituted benzyl and phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3kinase γ. MBCF meeting, Clearwater Beach, Feb. 26-March 1, 2006.
111. Rueckle, T., Jiang, X., Gaillard, P., Church, D. D. & Vallotton, T. Preparation of azolidinone-vinyl fusedbenzene derivatives for therapeutic uses as PI3 kinase inhibitors. PCT Int. Appl., WO-04007491 (2004).
112. Rueckle, T. et al. Identification and development of azolidinone vinyl-fused benzene derivatives, as potent and selective PI3Kγ inhibitors, orally active in models of rheumatoid arthritis. Abstracts of Papers, 230th National Meeting of the American Chemical Society, Washington, DC, August. 28 through September 1 2005.
113. Para, K. S., Stankovic, C. J. & Visnick, M. Preparation of 3-substituted indoles as inhibitors of phosphoinositide-3 kinases (PI3Ks PCT Int. Appl., WO-04108708 (2004).
114. Gogliotti, R. D., Lee, H. T., Sexton, K. E. & Visnick, M. Preparation of tetrazolyl benzofurancarboxamides as phosphoinositide-3-kinase (PI3K) inhibitors for the treatment of cancer, inflammatory and cardiovascular diseases. PCT Int. Appl., WO-04108709 (2004).
115. Connolly, M. et al. Preparation of N-tetrazolyl benzo [b#]thiophenecarboxamides as phosphoinositide-3-kinase (PI3K) inhibitors for the treatment of cancer, inflammatory and cardiovascular diseases. PCT Int. Appl., WO-04108713 (2004).
116. Bruendl, M. M. et al. Preparation of N-tetrazolyl benz o[b]thiophenecarboxamides as phosphoinositide-3-kinase (PI3K) inhibitors for the treatment of cancer, inflammatory and cardiovascular diseases. PCT Int. Appl., WO-04108715 (2004).
117. Connolly, M. K., Gogliotti, R. D., Hurt, C. R., Reichard, G. A. & Visnick, M. Preparation of halo-substituted N-tetrazolylbenzo[b]thiophenecarboxamid es with PI3K inhibitory activity as therapeutic agents. PCT Int. Appl., WO-05023800 (2005).
118. Connolly, M. K., Gogliotti, R. D., Plummer, M. S. & Visnick, M. Preparation of morpholinyl-pyrimidine derivatives as inhibitors of phosphoinositide-3-kinases. PCT Int. Appl., WO-05042519 (2005).
119. Wrasidlo, W. et al. Preparation of vasculostatic agents and methods of use. PCT Int. Appl., WO-04030635 (2004).
120. Wrasidlo, W. Discovery of 3,3′-(2,4-diaminopteridine-6,7-diyl)diphenol, a PI3K inhibitor with potent activity against vascular leakage. Proceedings of MedChem Europe (Molecules that matter: Case studies in medicinal chemistry); Berlin, April, 13-14, 2005.
121. Shimada, M. et al. Preparation of fused azolepyrimidine derivatives as PI3K inhibitors with therapeutic uses. PCT Int. Appl., WO-04029055 (2004).
122. Kuang, R-R., Qian, F., Li, Z. & Wei, D-Z. Study on improving the selectivity of compounds that inhibit two PI3Ks (γ and δ). J. Mol. Model. 12, 445-452 (2006).
123. Kuang, R.-R., Qian, F., Li, Z., Wei, D.-Z. & Tang, Y. Action mechanisms and structure-activity relationships of PI3Kγ inhibitors on the enzyme: a molecular modeling study. Eur. J. Med. Chem. 41, 558-565 (2006).
124. Knight, Z. A. & Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005).
125. Pope, R. M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nature Rev. Immunol. 2, 527-535 (2002).
126. Ali, K. et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 431, 1007-1011 (2004).
127. Yum, H. K. et al. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. J. Immunol. 167, 6601-6608 (2001).
128. Alloatti, G. et al. Phosphoinositide 3-kinase γ-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc. Res. 60, 242-249 (2003).
129. Alloatti, G. et al. Phosphoinositide 3-kinase γ controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. FEBS Lett. 579, 133-140 (2005).
130. Zhao, M. et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-γ and PTEN. Nature 442, 457-460 (2006).
131. Gammill, R. B., Judge, T. M. & Morris, J. Preparation of antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones. PCT Int. Appl., WO-9119707 (1991).
132. Hayakawa, M. et al. Preparation of condensed heteroaryl derivatives as phosphatidylinositol 3-kinase inhibitors and anticancer agents. PCT Int. Appl., WO-01083456 (2001).
133. Hayakawa, M. et al. Preparation of imidazopyridine derivatives as phosphatidylinositol 3-kinase inhibitors and anticancer agents. PCT Int. Appl., WO-01083481 (2001).
134. Melese, T., Perkins, E. L., Nguyen, A. T. Q. & Sun, D. Quinolin-2-ones and isoxazolo[3,4-c]quinolin-2-ones as modulators of phosphoinositide 3-kinase. PCT Int. Appl., WO-03035618 (2003).
135. Melese, T., Perkins, E. L., Nguyen, A. T. Q. & Sun, D. C yclohexothienopyrimidotriazoles and tetrahydropyran othienopyrimidotriazoles as modulators of phosphoinositide 3-kinase. PCT Int. Appl., WO-03034997 (2003).
136. Chang, J., Xie, W. & Wang, L. Preparation of naphthoquinone derivatives as PI3 kinase inhibitors for treatment of cancer. Faming Zhuanli Shenqing Gongkai Shuomingshu, CN 1587255 (2004).
137. Garlich, J. R., Durden, D. L., Patterson, M., Su, J. & Suhr, R. G. Preparation of quaternized derivatives of (morpholinyl)phenylbenzopyranone as PI-3 kinase inhibitor prodrugs. PCT Int. Appl., WO-04089925 (2004).
138. Nuss, J. M., Pecchi, S. & Renhowe, P. A. Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer. PCT Int. Appl., WO-04048365 (2004).
139. Drees, B. E. et al. 2-Thioxo-oxazolidine inhibitors of phosphatidylinositol 3-kinase and their use in treatment of cancer, inflammation, and immune diseases. PCT Int. Appl., WO-05002514 (2005).
140. Drees, B. E. et al. Preparation of pyrazoloquinolines and related derivatives as inhibitors of phosphatidylinositol 3-kinase. PCT Int. Appl., WO-05016245 (2005).
141. Kawashima, S. et al. Preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and 2-benzimidazolyl-4,6-dimorpholinyltriazine derivatives as antitumor agents. PCT Int. Appl., WO-05095389 (2005).
142. Bailey, J. P., Giles, M. B. & Pass, M. Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3 kinase inhibitors for treatment of cancer. PCT Int. Appl., WO-06005914 (2006).
143. Pass, M. Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors and their use in the treatment of cancer. PCT Int. Appl., WO-06005915 (2006).
144. Pass, M. Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase (PI3 kinase) inhibitors and their use in the treatment of cancer. PCT Int. Appl., WO-06005918 (2006).
145. Betzemeier, B. et al. Preparation of thiazoloindazoles for treatment and prevention of cancer. PCT Int. Appl., WO-06040281 (2006).
146. Zask, A. et al. Analogs of 17-hydroxywortmannin as PI3K inhibitors. PCT Int. Appl., WO-06044453 (2006).
147. Shuttleworth, S. J. et al. Pharmaceutical compounds as PI3K inhibitors. PCT Int. Appl., WO-06046040 (2006).
148. Shuttleworth, S. J. et al. Pharmaceutical compound as PI3K inhibitors. PCT Int. Appl., WO-06046031 (2006).
149. Bengtsson, M. et al. 5-heteroaryl thiazoles and their use as PI3K inhibitors. PCT Int. Appl., WO-06051270 (2006).
150. Andersen, R. et al. Meroterpenoid inhibitors of phosphoinositide 3 kinase (PI3K). PCT Int. Appl., WO-06081659 (2006).
151. Marion, F. et al. Liphagal, a selective inhibitor of PI3 kinase α isolated from the sponge Aka coralliphaga: Structure elucidation and biomimetic synthesis. Org. Lett. 8, 321-324 (2006).
152. Robertson, A. D. et al. Preparation and formulation of morpholino-substituted heterocycles as phosphoinositide 3-kinase inhibitors for therapeutic use. PCT Int. Appl., WO-01053266 (2001).
153. Jackson, S. P. et al. Preparation of morpholinyl- and pyridinyl-substituted heterobicyclic ketones as selective inhibitors of phosphoinositide 3-kinase β for use against thrombosis. PCT Int. Appl., WO-04016607 (2004).
154. Sadhu, C. et al. Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase δ. PCT Int. Appl., WO-01081346 (2001).
155. Sadhu, C. et al. Preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ. PCT Int. Appl., WO-03035075 (2003).
156. Shuttleworth, S. J. et al. Pharmaceutical compounds as PI3K inhibitors. PCT Int. Appl., WO-06046035 (2006).
157. Gogliotti, R. D., Lee, H. T., Sexton, K. E. & Visnick, M. 3-arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents. PCT Int. Appl., WO-04108716 (2004).
158. Gogliotti, R. D., Lee, H. T., Sexton, K. E. & Visnick, M. A preparation of (cycloalkylsulfanyl)benzo[b]thiophene derivatives, useful as selective PI3Kγ inhibitors. PCT Int. Appl., WO-04108714 (2004).
159. Rueckle, T., Shaw, J., Church, D. D. & Covini, D. Preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors. WO-05011686 (2005).
160. Rueckle, T. et al. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors. PCT Int. Appl., WO-06024666 (2006).